Immune checkpoint inhibitors (ICIs), including anti-PD-1, anti-PD-L1, and anti-CTLA-4 antibodies, have revolutionized cancer immunotherapy by activating cytotoxic T lymphocytes against tumors (Topalian et al., 2015). The gene discussed is CTLA4; the disease is cancer.